Boston Globe - Genentech says if a sale goes through, it has the right to bid on Biogen Idec's share of Rituxen, a treatment for non-Hodgkins lymphoma and rheumatoid arthritis. Genentech and Biogen Idec are already locked in arbitration over Genentech's claims ...
